Friedreich Ataxia Collaborative Clinical Research Network and Natural History Research Project We want  to inform you that Dr. Antoine Duquette, a neurologist at the CHUM,...

ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical...

Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system...

This is a review article focusing on the insights into the pathogenesis of this disorder and how those insights are being translated into novel therapeutic...